DK2421541T3 - : ny anvendelse - Google Patents

: ny anvendelse Download PDF

Info

Publication number
DK2421541T3
DK2421541T3 DK10714956.9T DK10714956T DK2421541T3 DK 2421541 T3 DK2421541 T3 DK 2421541T3 DK 10714956 T DK10714956 T DK 10714956T DK 2421541 T3 DK2421541 T3 DK 2421541T3
Authority
DK
Denmark
Prior art keywords
cells
gal
gos
tnf
mip
Prior art date
Application number
DK10714956.9T
Other languages
English (en)
Inventor
Georgios Tzortzis
Jelena Vulevic
Francesco Attanasio
Original Assignee
Clasado Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40774842&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2421541(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Clasado Inc filed Critical Clasado Inc
Application granted granted Critical
Publication of DK2421541T3 publication Critical patent/DK2421541T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)

Claims (2)

1. Galactooligosaccharid med en polymerisationsgrad på 3 eller derover, hvilket galactooligosaccharid er valgt fra gruppen bestående af trisaccharider Gal (β 1-6) - Gal (β 1-4) - Glc, Gal (β 1-3) - Gal (β 1-4) - Glc, tetrasaccharid Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc og pentasaccharid Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-6) - Gal (β 1-4) - Glc til anvendelse i forebyggelse af en intestinal inflammatorisk sygdom.
2. Galactooligosaccharidet ifølge krav 1 til anvendelsen ifølge krav 1 anvendt som et pulver eller en sirup.
DK10714956.9T 2009-04-23 2010-04-23 : ny anvendelse DK2421541T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0906983.2A GB0906983D0 (en) 2009-04-23 2009-04-23 Novel use
GBGB0920784.6A GB0920784D0 (en) 2009-04-23 2009-11-27 Novel use
PCT/GB2010/050659 WO2010122344A1 (en) 2009-04-23 2010-04-23 Novel use

Publications (1)

Publication Number Publication Date
DK2421541T3 true DK2421541T3 (da) 2018-09-24

Family

ID=40774842

Family Applications (1)

Application Number Title Priority Date Filing Date
DK10714956.9T DK2421541T3 (da) 2009-04-23 2010-04-23 : ny anvendelse

Country Status (25)

Country Link
US (1) US20120058972A1 (da)
EP (1) EP2421541B1 (da)
JP (1) JP2012524770A (da)
KR (1) KR20110138416A (da)
CN (1) CN102427818A (da)
AU (1) AU2010240642B2 (da)
BR (1) BRPI1015091A2 (da)
CA (1) CA2759442C (da)
CY (1) CY1120597T1 (da)
DK (1) DK2421541T3 (da)
ES (1) ES2688786T3 (da)
GB (3) GB0906983D0 (da)
HU (1) HUE040451T2 (da)
IL (1) IL215855A0 (da)
MX (1) MX341308B (da)
MY (1) MY151104A (da)
NZ (1) NZ595969A (da)
PL (1) PL2421541T3 (da)
PT (1) PT2421541T (da)
RU (1) RU2530567C2 (da)
SG (1) SG175313A1 (da)
TR (1) TR201810868T4 (da)
UA (1) UA106491C2 (da)
WO (1) WO2010122344A1 (da)
ZA (1) ZA201107821B (da)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2492559B (en) * 2011-07-05 2018-07-25 Clasado Inc Composition and method for preventing or reducing the risk of developing a syndrome
CA2842672A1 (en) 2011-07-22 2013-01-31 Abbott Laboratories Galactooligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN103716787B (zh) 2012-09-29 2020-06-23 北京三星通信技术研究有限公司 一种支持对家用基站进行验证的方法
CN107158011A (zh) * 2017-05-25 2017-09-15 浙江大学 低聚半乳糖在制备治疗肠道疾病的药物中的用途
AU2020275468A1 (en) * 2019-05-15 2021-12-02 N.V. Nutricia Beta-1,3'-galactosyllactose for the treatment of gut barrier function diseases
EP4362708A1 (en) * 2021-07-01 2024-05-08 N.V. Nutricia Nutritonal compositions for gut barrier function
KR102453998B1 (ko) * 2022-01-07 2022-10-14 (주)네오크레마 갈락토올리고당을 포함하는 염증성 장질환의 예방, 개선 또는 치료용 조성물
GB2619977A (en) * 2022-06-24 2023-12-27 Clasado Res Services Limited Compositions and uses thereof
GB2623335A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof
GB2623336A (en) * 2022-10-12 2024-04-17 Clasado Res Services Limited Compositions and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0229015D0 (en) * 2002-12-12 2003-01-15 Novartis Nutrition Ag New Compound
GB0315266D0 (en) * 2003-06-30 2003-08-06 Clasado Inc Novel galactooligosaccharide composition and the preparation thereof
ATE360682T1 (de) * 2003-06-30 2007-05-15 Clasado Inc Neue galactooligosaccharidzusammensetzung und herstellung davon
EP1597978A1 (en) 2004-05-17 2005-11-23 Nutricia N.V. Synergism of GOS and polyfructose
EP1887017A1 (en) * 2006-08-09 2008-02-13 Friesland Brands B.V. Prebiotic carbohydrate
GB0809921D0 (en) * 2008-05-30 2008-07-09 Clasado Inc Product and process therefor

Also Published As

Publication number Publication date
US20120058972A1 (en) 2012-03-08
EP2421541A1 (en) 2012-02-29
GB2482817B (en) 2014-02-26
CA2759442A1 (en) 2010-10-28
MX2011011159A (es) 2011-11-07
RU2011147390A (ru) 2013-05-27
GB201120030D0 (en) 2012-01-04
ZA201107821B (en) 2012-07-25
TR201810868T4 (tr) 2018-08-27
UA106491C2 (uk) 2014-09-10
SG175313A1 (en) 2011-11-28
IL215855A0 (en) 2012-01-31
PT2421541T (pt) 2018-10-15
CN102427818A (zh) 2012-04-25
PL2421541T3 (pl) 2018-11-30
MX341308B (es) 2016-08-12
KR20110138416A (ko) 2011-12-27
GB0906983D0 (en) 2009-06-03
EP2421541B1 (en) 2018-07-11
BRPI1015091A2 (pt) 2016-04-26
NZ595969A (en) 2013-03-28
JP2012524770A (ja) 2012-10-18
GB0920784D0 (en) 2010-01-13
HUE040451T2 (hu) 2019-03-28
CY1120597T1 (el) 2019-12-11
ES2688786T3 (es) 2018-11-06
GB2482817A (en) 2012-02-15
AU2010240642B2 (en) 2013-03-14
AU2010240642A1 (en) 2011-11-10
MY151104A (en) 2014-04-15
WO2010122344A1 (en) 2010-10-28
CA2759442C (en) 2016-01-19
RU2530567C2 (ru) 2014-10-10

Similar Documents

Publication Publication Date Title
DK2421541T3 (da) : ny anvendelse
US20110082102A1 (en) Use of prebiotic galacto-oligosaccharides in the treatment of intestinal inflammation
Nijman et al. Characterization and quantification of oligosaccharides in human milk and infant formula
Newburg et al. Human milk oligosaccharides and synthetic galactosyloligosaccharides contain 3′-, 4-, and 6′-galactosyllactose and attenuate inflammation in human T84, NCM-460, and H4 cells and intestinal tissue ex vivo
AU2015262214B2 (en) Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from Akkermansia muciniphila bacteria
Machado et al. Gut microbiota and nonalcoholic fatty liver disease
A. Parnell et al. Prebiotic fiber modulation of the gut microbiota improves risk factors for obesity and the metabolic syndrome
US8425930B2 (en) Prebiotic oligosaccharides
Dong et al. In vitro fermentation of oat β‐glucan and hydrolysates by fecal microbiota and selected probiotic strains
Fernández Fernández et al. Healthy effects of prebiotics and their metabolites against intestinal diseases and colorectal cancer
US20140303067A1 (en) Treatment of eosinophilic esophagitis
Diez-Municio et al. Efficient synthesis and characterization of lactulosucrose by Leuconostoc mesenteroides B-512F dextransucrase
Wu et al. Butyrolactone-I, an efficient α-glucosidase inhibitor, improves type 2 diabetes with potent TNF-α–lowering properties through modulating gut microbiota in db/db mice
Ceresola et al. Targeting patients' microbiota with probiotics and natural fibers in adults and children with constipation.
Sato et al. An effectiveness study of hyaluronic acid [Hyabest®(J)] in the treatment of osteoarthritis of the knee on the patients in the United States
Palanivel et al. Obesity‐induced immunological effects on the skin
Macfarlane et al. Food and the large intestine
Ambrogi et al. Bifidobacterial β-galactosidase-mediated production of galacto-oligosaccharides: structural and preliminary functional assessments
CA3214678A1 (en) Methods of use of oligosaccharide compositions for modulating microbiota and their metabolic products, and as therapeutics for health applications
Bessa et al. Kefir as a therapeutic agent in clinical research: a scoping review
Manchanayake The Impact of Gut Microbiota on Host Obesity. J Gastrointest Dig Syst 9: 591. doi: 10.4172/2161-069X. 1000591 Page 2 of 8 J Gastrointest Dig Syst, an open access journal ISSN: 2161-069X Volume 9• Issue 1• 1000591
US20140212494A1 (en) Methods of Improving Digestive Health